ArticleIn vivo (Athens, Greece)
Influence of Residual Motion Within the Gating Window on Dose Distribution in Respiratory-gated Proton Therapy.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimRespiratory-gated proton therapy can mitigate interplay effects between the proton beam and target motion. However, the residual motion of the target within the gating window (GW) may still cause clinically relevant dosimetric variations. This study aimed to evaluate target and normal-tissue doses associated with residual motion within the GW. PATIENTS AND
methodsEight patients with non-small cell lung cancer were analyzed. For each GW setting, the internal clinical target volume (iCTV) was defined as the union of clinical target volumes (CTVs) within the GW. Maximum residual motion (MRM) was defined as the maximum CTV motion within the GW relative to the 50% phase. Treatment plans were generated for single-field uniform dose (SFUD) and intensity-modulated proton therapy (IMPT). Dynamic 4D dose (D4DD) was calculated, and differences in dose metrics between the treatment plan and D4DD (ΔDM) were evaluated for CTV D
resultsIncreasing MRM was associated with decreased CTV D
conclusionWhen MRM was <3 mm, ΔDM for both the target and lungs were within ±3%. Therefore, selecting a GW that limits MRM to <3 mm may represent an appropriate criterion for both SFUD and IMPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.